



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/20, 31/725		A1	(11) International Publication Number: WO 97/21434 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/US95/16722 (22) International Filing Date: 11 December 1995 (11.12.95)		(81) Designated States: AU, BR, CA, FI, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(71) Applicant (<i>for all designated States except US</i>): INHOLTRA, INC. [US/US]; 16270 Cranberry Court, Davie, FL 33331 (US). (71)(72) Applicant and Inventor: FLORIO, Vito, V. [US/US]; 9501 W. McNab Road, Tamarac, FL 33321 (US). (74) Agent: FARO, John, H.; Faro & Associates, 3341 S.W. 15th Street, Pompano Beach, FL 33069 (US).			

(54) Title: DIETARY REGIMEN OF NUTRITIONAL SUPPLEMENTS FOR RELIEF OF SYMPTOMS OF ARTHRITIS

(57) Abstract

This invention is directed to a dietary regimen and a unique combination of nutritional supplements and a method. More specifically, this invention is directed to a unique combination of nutritional supplements which provides symptomatic relief from arthritis. The unique combination of nutritional supplements of this invention is believed to function by both increasing the available (effective blood level) of anti-inflammatory agents and promotion of the healing/regenerative process in the effected joints, thus, producing unexpected and lasting symptomatic relief from the debilitating effects of both osteoarthritis and rheumatoid arthritis. The essential nutritional supplements of the dietary regimen of this invention are as follows: (a) gamma linolenic acid (unrefined), hereinafter "GLA"; (b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter collectively "EPA"; (c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, glucosamine sulfate and manganese aspartate, hereinafter collectively "CHONDROX". The regimen is adjusted based upon the weight of the individual, and once symptomatic relief is achieved, the individual remains essentially free from the debilitating effects of arthritis so as long the daily regimen is faithfully followed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE OF INVENTION

*Dietary Regimen Of Nutritional Supplements
For Relief Of Symptoms Of Arthritis*

5

BACKGROUND OF THE INVENTION

1. **Field Of The Invention:** This invention is directed to a unique combination of nutritional supplements and a method.. More specifically, this invention is directed to a unique combination of nutritional supplements which provides symptomatic relief from arthritis. The unique combination of nutritional supplements of this invention is believed to 10 function by increasing the available (effective blood level) of anti-inflammatory agents and, thus, unexpected and lasting symptomatic relief from the debilitating effects of both osteoarthritis and rheumatoid arthritis.

15 2. **Description Of The Prior Art:** Osteoarthritis or degenerative joint disease is the most common form of arthritis. It is seen primarily, but not exclusively, in the elderly; surveys have indicated that 80% of persons over the age of 50 have osteoarthritis. Under the age of 45, osteoarthritis is much more common in men; after age 45 it is ten times more common in women than men.

The weight-bearing joints and joints of the hands are the joints principally affected by 20 the generative changes associated with osteoarthritis. Specifically, there is much cartilage destruction, followed by hardening, and the formation of large bone spurs (Calcified osteophytes) in the joint margins. Pain, deformity and limitation of motion in the joint results. Inflammation is usually minimal.

Osteoarthritis is divided into two categories, primary and secondary osteoarthritis. In 25 primary osteoarthritis, the degenerative wear-and-tear process occurs after the fifth and sixth decades, with no predisposing abnormality apparent. The cumulative effects of decades of use leads to the degenerative changes by stressing the integrity of the collagen matrix of the cartilage. Damage to the cartilage results in the release of enzymes that destroy collagen

components. With aging, there is a decreased ability to restore and synthesize normal collagen structures.

Secondary osteoarthritis is associated with some predisposing factor responsible for the degenerative changes. Various predisposing factors in secondary osteoarthritis include 5 congenital abnormalities in joint structure or function (e.g. excessive joint mobility and abnormally shaped joint surfaces), trauma (obesity, fractures along joint surcades, surgery, etc.) crystal deposition, presence of abnormal cartilage, and previous inflammatory disease of joint (rheumatoid arthritis, gout, septic arthritis, etc.).

The causes of osteoarthritis are, thus, perceived believed to include one or more of 10 the following conditions or imbalances in the body's chemistry:

- Excessive mobility/joint instability.
- Age-related changes in collagen matrix repair mechanisms.
- Hormonal and sex factors.
- Altered biochemistry.
- 15 • Genetic predisposition.
- Inflammation.
- Fractures and mechanical damage.
- Inflammatory joint disease.
- Others.

20 As anyone who has been afflicted by this disease can attest, the onset of osteoarthritis can be very subtle, morning joint stiffness often being the first symptom. As the disease progresses, there is pain on motion of the involved joint, that is made worse by prolonged activity and relieved by rest. There are usually no signs of inflammation.

The specific clinical picture varies with the joint involved. Disease of the hands leads 25 to pain and limitation of use. Knee involvement produces pain, swelling and instability. Osteoarthritis of the hip causes local pain and a limp. Spinal osteoarthritis is very common and may result in compression of nerves and blood vessels, causing pain and vascular insufficiency,

The classic presentation of osteoarthritis is easy to distinguish from other types of arthritis, especially rheumatoid arthritis, which is usually associated with much more inflammation of surrounding soft tissues.

5 The data collected from the earliest signs of osteoarthritis to the most advanced stages suggest that cellular and tissue response to osteoarthritis (OA) is purposeful and is aimed at repair of the damaged joint structure; and, that the process contributing to OA thus appears to be able to be arrested and sometimes reversed. Accordingly, the major therapeutic goal appears to be enhancing repair processes by various connective tissue cells.

10 Several studies have attempted to determine the "natural course" of OA. In one case study the natural course of OA of the hip was studied over a ten-year period. All subjects had changes suggestive of advanced osteoarthritis, yet the researchers reported marked clinical improvement and radiological recovery of the joint space in 14 of 31 hips. The authors purposely applied no therapy and regarded their results as reflecting the natural course of the disease.

15 These results as well as others raise some interesting questions. Does medical intervention in some way promote disease progression? Can various natural therapies enhance the body's own response towards health? The answer to both of these questions appears to be yes.

Medication & Side Effects

20 The first drug generally employed in the treatment of osteoarthritis is aspirin. It is often quite effective in relieving both the pain and inflammation. It is also relatively inexpensive. However, since the therapeutic dose required is relatively high (2 to 4 grams per day), toxicity often occurs. Tinnitus (ringing in the ears) and gastric irritation are early manifestations of toxicity.

25 Other non-steroidal anti-inflammatory drugs (NSAIDs) are often used as well, especially when aspirin is ineffective or intolerable - ibuprofen (Brufen, Motrin), fenoprofen (Fenopron), indomethacin (Indocid), naproxen (Naprosyn), tolmetin (Tolectrin) and sulindac (Clinoril). These drugs are also associated with side effects including

gastrointestinal upset, headaches and dizziness, and are therefore recommended for only short periods of time.

One side effect of aspirin and other NSAIDs that is often not mentioned is their inhibition of cartilage repair (i.e. inhibition of collagen matrix synthesis) and acceleration of cartilage destruction in experimental studies. Since osteoarthritis is caused by a degeneration of cartilage it appears that, while NSAIDs are fairly effective in suppressing the symptoms, they possibly worsen the condition by inhibiting cartilage formation and accelerating cartilage destruction. This adverse effect of NSAID therapy has been upheld in studies which have shown that NSAIDs use is associated with acceleration of osteoarthritis and increased joint destruction. Simply stated, NSAIDs appear to suppress the symptoms but accelerate the progression of osteoarthritis.

Dietary Regimen Effect On Disease

Alternatives to medication include a dietary regimen which may exclude the consumption of some foods and/or the use of certain nutritional supplements. Primary dietary therapy involves the achievement of normal body weight; excess weight means increased stress on weight-bearing joints affected with osteoarthritis. A general healthy diet rich in complex carbohydrate and dietary fiber is recommended.

Childers, a horticulturist, popularized a diet in the treatment of osteoarthritis that eliminated foods from the genus *solanaceae* (nightshade family) after finding this simple dietary elimination cured his osteoarthritis. Childers developed a theory that genetically susceptible individuals might develop arthritis, as well as a variety of other complaints, from long-term low level consumption of solanum alkaloids that are found in tomatoes, potatoes, eggplant, peppers and tobacco. Presumably these alkaloids inhibit normal collagen repair in the joints or promote the inflammatory degeneration of the joint. Although remaining to be proved, this diet may offer some benefit to certain individuals.

It has and continues to be increasingly accepted that nutritional considerations, specifically, the consumption of nutritional supplements, can control and reverse the pain and crippling effects of arthritis. The following is representative of some of the more credible clinical investigation with respect to certain nutritional supplements.

5 *Niacinamide* - Dr. William Kaufman has reported very good clinical results in the treatment of hundreds of patients with rheumatoid and osteoarthritis using high dose niacinamide (i.e. 900 mcg to 4 g in divided dose daily). Niacinamide at this high dose can result in significant side effects (glucose intolerance, liver damage) and should therefore be
5 instituted under strict medical supervision.

10 *Methionine* - The essential amino acid methionine, administered as S-adenosyl-methionine, was shown to be superior to ibuprofen (Motrin) in the treatment osteoarthritis in a double-blind clinical trial. The positive effect in this trial is consistent with several other clinical studies. Methionine is a sulfur-containing amino acid which is very important in
10 cartilage structures, especially proteoglycans and glycosaminoglycans,

15 *Glycosaminoglycans* - Injectable glycosaminoglycan polysulphate and activated acid-pepsin-digested calf tracheal cartilage as well as other glycosaminoglycan preparations have yielded positive results in controlled trials and experimental studies. Results seem to indicate these compounds may address some of the underlying causes of the degenerative process
15 characteristic of osteoarthritis.

20 It must be pointed out that these latter studies have all utilized injectable formulas. It is highly unlikely similar results could be obtained with these formulations when administered orally as intestinal absorption of glycosaminoglycans having a molecular weight greater than 4,000 is quite poor without the aid of special vehicles, such as liposomes, or possible enteric-coating.

25 Many commercial products are available that contain chondroitin sulfate (molecular weight 30,000). It must be pointed out the majority of these formulas are probably of no greater benefit than placebo as chondroitin sulfate is not absorbed to any significant degree. Enteric locating or administering in the form of a liposome may increase bio-availability but this has yet to be fully determined. In addition, it is possible that smaller fragments of the molecule may have some therapeutic effect, but again this has yet to be determined.

Superoxide Dismutase - Like glycosainoglycan preparations, intra-articular injection of superoxide dismutase (SOD) has demonstrated significant therapeutic effects in the

treatment of OA. Whether oral SOD preparations are absorbed orally has yet to be determined. Preliminary indications are that it is probably not.

5 *Vitamin E* - A clinical trial using 600 iu of vitamin E in patients with osteoarthritis demonstrated significant benefit from the vitamin E. The benefit was thought to be due to vitamin E's antioxidant and membrane stabilizing actions. Later studies have shown that vitamin E has an ability to inhibit the enzymatic breakdown of cartilage as well as stimulate cartilage synthesis.

10 *Vitamin C* - Deficient vitamin C intake is common in the elderly, resulting in altered collagen synthesis and compromised connective tissue repair. Several studies have demonstrated that vitamin C has a positive effect on cartilage, and one confirmed the importance, indeed necessity, for an excess of ascorbic acid in human chondrocyte protein synthesis. In a study of experimental OA in guinea pigs cartilage erosion was found to be much less and the overall changes in and around the OA joint milder in animals kept on high doses of vitamin C.

15 Vitamin C and E appear to possess synergistic effects. Thus, both vitamins E and C appear to enhance the stability of sulfated proteoglycans in the complex structure comprising articular cartilage. Judicious use of these vitamins in the treatment of osteoarthritis, either alone or in combination with other therapeutic means, may thus be of great benefit to the patient population by retarding the erosion of cartilage.

20 *Pantothenic Acid* - Acute deficiency of pantothenic acid in the rat causes a pronounced failure of cartilage growth and eventually produces similar lesions to osteoarthritis. This implicates low pantothenic acid levels in the development of human OA. Clinical improvements in OA symptomatology has been reported with the daily supplementation of 12.5 mg pantothenic acid, although such results often took 7-14 days 25 before manifesting. (A larger double-blind study in patients with primarily rheumatoid arthritis displayed no significant benefit with 500 mg pantothenic acid administration.)

Vitamins A, B6 and E, Zinc and Copper - These nutrients are required for the synthesis of normal collagen and maintenance of cartilage structures. A deficiency of any one of these would allow accelerated joint degeneration.

Physical Therapy

Various physical therapies (exercise, heat, cold, diathermy, ultrasound, etc.) are often very beneficial in improving joint mobility and reducing pain in sufferers of OA. The importance of physical therapy appears to be quite significant, especially when administered regularly. Much of the benefit of physical therapy is thought to be a result of achieving a proper water content within the joint capsule.

Clinical and experimental studies seem to indicate short-wave diathermy may be of the greatest benefit. Combining short-wave diathermy therapy with periodic ice massage, rest and appropriate exercises appears to be the most sensible approach. Proper exercises include isometric exercises and swimming; these types of exercises increase circulation to the joint and strengthen surrounding muscles without placing too much strain on the joint.

In summary, the cause, progression and treatment of the disease presents a complex and has up to now generally required a multi-phasic approach to proper treatment. More specifically, to the extent that consumption of certain foods is believed to influence the progression of the disease, all simple, processed and concentrated carbohydrates must be avoided. In addition, complex-carbohydrate, high-fiber foods should be stressed and fats should be kept to a minimum. Moreover, plants of the *solanaceae* family should be eliminated (tomatoes, potatoes, eggplant, peppers and tobacco).

Where the disease is influenced by the consumption of dietary supplements, one or more of the supplements discussed above are available as an option, however, medical supervision is generally recommended. In addition, daily exercises including isometric exercises and swimming short-wave diathermy and other physical therapy treatments may be helpful.

As is evident from the foregoing, the treatment of OA involves both the abatement of the pain associated with the disease and the fostering of healing of the effected tissues. The use of the common analgesics (e.g. aspirin, ibuprofen, etc.) while relieving the pain may in fact accelerate the progression of the disease by inhibition of the healing processes associated with cartilage repair. Moreover, the attempts to treat the disease by the focusing upon a single natural occurring compound, or limited number of compounds, has generally resulted

in only limited and short term improvements. Accordingly, there continues to be a need for a safe and effective regimen for the treatment of OA but yet is affordable and does not require the supervision of a medical professional.

5

OBJECTS OF THE INVENTION

It is the object of this invention to remedy the above as well as related deficiencies in the prior art.

More specifically, it is the principle object of this invention to provide a unique combination of nutritional supplements in effective amounts, taken in a prescribed sequence, 10 which is both safe and effective to relieve the debilitating symptom of arthritis.

It is another object of this invention to provide a unique combination of nutritional supplements in effective amounts, taken in a prescribed sequence, which apparently permits extended relief from lower dosage of these agents.

It is still yet another object of this invention to provide a unique combination of 15 nutritional supplements in effective amounts, taken in a prescribed sequence which is easily digestible, thus, free from many of the side-effects associated with the more common anti-inflammatory medicines.

Additional objects include a method for the relief of symptoms of arthritis through the ingestion of effective amounts of readily digestible nutritional supplements.

20

SUMMARY OF THE INVENTION

The above and related objects are achieved by the provision of unique combination of 25 nutritional supplements in effective amounts, taken in a prescribed sequence, to produce a readily ingestible formulation that relieves the symptomatic pain associated with the more common forms of arthritis.

In brief, this invention comprises a unique combination of nutritional supplements in effective amounts, taken in a prescribed sequence that reportedly have some demonstrated effectiveness in the treatment of the debilitating effects of arthritis, together a chondroitinsulfuric acid salt, (a constituent of healthy cartilage) to provide symptomatic relief

from the pain associated with arthritis. The precise mechanism or physiology of action of the formulation on the afflicted individual is not known, nor the precise nature of the pain complex of this disease.

5 The following nutritional supplements, when taken in effective amounts and in the appropriate regimen provide both unexpected and lasting symptomatic relief from arthritis:

- (a) gamma linolenic acid (unrefined), hereinafter "GLA"
- (b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter "EPA"
- (c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, glucosamine sulfate and manganese aspartate, hereinafter "CHONDROX"

10 Generally, the commercially available preparations of the foregoing essential supplements contain additional ingredients, e.g. vitamins such as Vitamin E and C, in relatively minor amounts. It is believed that these additional ingredients, where present, are not believed to contribute to the efficacy of the supplement formulation; and, are simply 15 included for their anti-oxidant properties to enhance the shelf live of the commercial preparation.

It would appear that all of the above supplements are essential to complete pain relief, and that the gamma linoleic acid (GLA) is probably the principle ingredient in abating the symptomatic pain associated with the arthritic condition. Moreover, it also appears that the 20 effectiveness of GLA is linked to the presence of EPA in the diet; and, that the dietary demands for EPA in the above regimen is a function of the individuals weight.

It is further hypothesized that the combination of anti-inflammatory dietary supplement with chondroitinsulfuric acid salt not only reduces the inflammation of the joint in the afflicted area and but also permits the healing of the damaged cartilage. The precise 25 formulation is based upon body weight of the affected individual.

**DESCRIPTION OF THE INVENTION
INCLUDING PREFERRED EMBODIMENTS**

The formulation of the invention includes a unique combination of nutritional supplements in effective amounts, taken in a prescribed sequence, to effectively relieve the debilitating symptomatic conditions associated with arthritis.

In general, the unique combination of nutritional supplements of this invention includes a number constituents which are reported as providing anti-inflammatory therapy, and yet individually and in the reported combinations fail to provide the dramatic and long term relief afforded with this invention. More specifically, the unique combination of nutritional supplements of this invention include:

- (a) gamma linolenic acid (unrefined), hereinafter "GLA"
- 10 (b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter "EPA"
- (c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, glucosamine sulfate and manganese aspartate, hereinafter "CHONDROX"

15 Gamma linolenic acid (GLA) is generally present in a number of natural source, including specifically, from borage seed oil and other plant. There is some support in the literature that eicosapentaenoic acid is suitable in the treatment of rheumatoid arthritis.

Eicosapentaenoic acid and docosahexaneoic acid (collectively "EPA") is obtained from fish (e.g. sardines and mackerel). These constituents comprise highly unsaturated fatty acids, generally containing as many as five (5) unsaturated double bonds, and thus highly susceptible to oxidation. There is some support in the literature that eicosapentaenoic acid is efficacious in the treatment of rheumatoid arthritis.

20 Chondroitin sulfate is a high viscosity mucopolysaccharide with N-acetylchondrosine as a repeating unit and with one sulfate group per disaccharide unit. This compound can be prepared by any one of number of techniques disclosed in the technical literature (e.g. Schubert, *Fed. Proc.* 17, 1099 (1958)). This compound is generally found in the skeletal and soft connective tissue of the human body. There is some support in the literature that chondroitin sulfate is involved in the regeneration of cartilage and other connective tissues.

N-acetyl glucosamine sulfate and glucosamine sulfate are generally present in chitin, in mucoproteins and in mucopolysaccharides. There is some support in the literature that chondroitin sulfate is efficacious as an anti-arthritis. The N-acetyl glucosamine sulfate, glucosamine sulfate and chondroitin sulfate are taken together and thus collectively referred
5 as "CHONDROX"

A dietary regimen which includes each of the foregoing supplements, taken at the prescribed intervals and in the appropriate amounts, both relieves the debilitating effects of arthritis in the short term, and is believed to promote healing of the tissues in the inflamed joints. The precise regimen, as empirically determined, is apparently dependent upon body
10 weight, which appears to increase the body's requirements for GLA. This difference may also be gender dependent, women subjects generally weighing less than men in the test population for this therapy.

In one of the preferred embodiments of this invention, the following recommended regimen is both safe and effective for relief from the symptomatic effects of arthritis, without
15 the attendant side effects generally associated with medication.

Individuals Weighing Less Than 150 pounds

	<u>Dosage*</u>	<u>Supplement</u>	<u>Time of Day</u>
	1	CHONDROX	Morning
	1	EPA	Morning
20	1	CHONDROX	PM
	1	GLA	PM

*The recommended dosage is preferably an amount which is in excess of the minimum daily requirements for an individual's body weight and metabolism; and, is preferably a multiple (2x or 3x) of such minimum daily requirements (MDR). Where
25 no MDR is established for the supplement listed, the dosage the unit dosage should range from about 250 to 500 mg (alternatively, should parallel the dosage for the supplement that is taken at the same time period for which an MDR has been established).

Individuals Weighing More Than 150 pounds, but Less Than 200 pounds

<u>Dosage</u>	<u>Supplement</u>	<u>Time of Day</u>
2	CHONDROX	Morning
1	EPA	Morning
5 1	GLA	Morning
1	CHONDROX	Mid-Day
1	EPA	Mid-Day
1	CHONDROX	PM
1	GLA	PM

10 *Individuals Weighing More Than 200 pounds*

<u>Dosage</u>	<u>Supplement</u>	<u>Time of Day</u>
2	CHONDROX	Morning
1	EPA	Morning
1	GLA	Morning
15 2	CHONDROX	Mid-Day
1	EPA	Mid-Day
1	GLA	Mid-Day
2	CHONDROX	PM
1	EPA	PM
20 1	GLA	PM

As is evident from the foregoing, the body's demand for CHRONDOX requires that this supplement be taken a minimum of twice, and in heavier individuals, three times a day. The presence of EPA in the blood is known to inhibit the metabolism of the gamma linoleic acid (GLA), thus, EPA should be taken in the morning with the initial consumption of 25 CHRONDOX.

When the above regimen is followed, the pain associated with arthritis will begin to subside within about one (1) to two (2) days thereafter; and, provides essentially continuous relief so long as the regimen is followed. Where the regimen is discontinued, the debilitating pain will return within a relatively brief period (4-6 days). In some instances, the therapeutic

effects of the formulation provides pain relief for even a longer period (up to 14 days) after the regimen has been discontinued. Upon resumption of the regimen, the pain once again is abated, and no side effects are experienced even after several months of continuous use. Present experience indicates that essentially no adverse side effects have been experienced
5 after a year of continuous use.

In an effort to determine which of the various constituents is most essential to pain relief, one component of the supplement regimen is discontinued, and the results observed. This process is repeated so as to obtain a degree of insight and correlation of a supplements role in the dietary regimen. It would appear that all of the above supplements are essential
10 to complete pain relief, and that the gamma linoleic acid (GLA) is probably the principle ingredient in abating the symptomatic pain associated with the arthritic condition. Moreover, it also appears that the effectiveness of GLA is linked to the presence of EPA in the diet; and, that the dietary demands for EPA in the above regimen is a function of the individuals weight. The long term benefits of this regimen is apparently attributable to the
15 effectiveness of the chondroitin sulfate and N-acetyl glucosamine sulfate which apparently results in reversal of the cartilage deterioration and, thus, stabilization and repair of the afflicted joint.

The foregoing supplements are available in a variety of convenient forms and dosage levels to accommodate the foregoing regimen. For example, chondroitin sulfate and N-
20 acetyl glucosamine sulfate are available for the Prolongevity, Ltd. (The Life Extension Foundation) under the CHONDROX label - the typical capsule containing 250 mg each of and N-acetyl glucosamine sulfate and glucosamine, and 100 mg chondroitin sulfate. Similarly, eicosapentaenoic acid and docosahexaneoic acid are available for the Prolongevity,
25 Ltd. (The Life Extension Foundation) under the MEGA EPA label - the typical capsule containing 400 mg eicosapentaenoic acid, 300 mg docosahexaneoic acid, vitamin E (2 IU) and 2 mg vitamin C (both of such vitamins apparently being present for their anti-oxidant properties. . Similarly, Gamma linolenic acid is available for the Prolongevity, Ltd. (The Life Extension Foundation) under the MEGA GLA label - the typical capsule containing 300 mg gamma linolenic acid.

In the another of the preferred embodiments of this invention, the dietary supplements for a given time frame are incorporated into a unitary dose (capsule) or other palatable mixture.

The precise amount of the recommended supplement may have to be adjusted
5 depending upon the severity of individual's condition and the extent of progression of the disease. Notwithstanding, once the progression of the disease has been arrested, the foregoing regimen is effective to maintain the individuals freedom from pain and further progression of the disease.

The foregoing description has been provided to illustrated one or more of the
10 preferred embodiments of this invention and is not intended to delineate its scope which is set forth in the following claims.

WHAT IS CLAIMED IS:

1. A method for providing symptomatic relief from the debilitating effects of arthritis, including specifically, osteoarthritis, comprising:

5 (a) providing a dietary regimen which includes the consumption of the following supplements, in effective amounts, taken at the prescribed intervals during the day,

(a) gamma linolenic acid (unrefined), hereinafter "GLA"

(b) a mixture of eicosapentaenoic acid and docosahexaneoic acid, hereinafter collectively "EPA"

(c) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, and 10 glucosamine sulfate, hereinafter "CHONDROX"

with the proviso that CHONDROX and EPA be taken together at least once in the morning and that CHONDROX and GLA be taken together at least one in the evening; and

(b) maintaining the regimen of step (a) from day to day.

15 2. The method of Claim 1, wherein the regimen is adjusted for the weight of the individuals from in excess of about 150 pounds up to about 200 pounds as follows:

<u>Dosage</u>	<u>Supplement</u>	<u>Time of Day</u>
2	CHONDROX	Morning
1	EPA	Morning
20 1	GLA	Morning
1	CHONDROX	Mid-Day
1	EPA	Mid-Day
1	CHONDROX	PM
1	GLA	PM

25 said effective unit dosage of CHONDROX ranging from about 100 to about 200 mg, and said effective unit dosage of all other supplements ranging from about 250 to about 450 mg.

3. The method of Claim 1, wherein the regimen is adjusted for the weight of the individuals in excess of about 200 pounds as follows:

	<u>Dosage</u>	<u>Supplement</u>	<u>Time of Day</u>
	2	CHONDROX	Morning
5	1	EPA	Morning
	1	GLA	Morning
	2	CHONDROX	Mid-Day
	1	EPA	Mid-Day
	1	GLA	Mid-Day
10	2	CHONDROX	PM
	1	EPA	PM
	1	GLA	PM

said effective unit dosage of CHONDROX ranging from about 100 to about 200 mg, and said effective unit dosage of all other supplements ranging from about 250 to about 450 mg.

4. An article of manufacture including:

(a) unit packages in the form of capsules, tablets or liquids of the following dietary supplements

- 20 (i) gamma linolenic acid (unrefined), hereinafter "GLA";
- (ii) a mixture of eicosapentaenoic acid and docosahexanoic acid, hereinafter collectively "EPA";
- (iii) a mixture of chondroitin sulfate, N-acetyl glucosamine sulfate, and glucosamine sulfate, hereinafter "CHONDROX"; and
- 25 (b) written and/or graphic instructions, including a weight table, indicating the effective amount of each of the above supplements to be taken throughout the day for symptomatic relief from the debilitating effects of arthritis, including specifically, osteoarthritis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/16722

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/20, 31/725

US CL : 514/23, 62, 558

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/23, 62, 558

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 3,683,076 (ROVATI) 08 August 1972, see claim 1.	1-4
A	US, A, 4,843,095 (RUBIN) 27 June 1989, see claim 1.	1-4
A	US, A, 5,166,048 (SOLL ET AL.) 24 November 1992, see column 11, lines 12-20.	1-4
A	US, A, 5,364,845 (HENDERSON) 15 November 1994, see column 7, lines 36-49.	1-4
A	EP, A, 0,609,001 (HORROBIN ET AL.) 03 August 1994, see page 3, line 55 to page 4, line 23.	1-4
A	GB, A, 2,223,943 (PLÜSS) 25 April 1990, see page 4, lines 5-26.	1-4

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

27 MARCH 1996

Date of mailing of the international search report

09 APR 1996


Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KATHLEEN KAHLER FONDA

Telephone No. (703) 308-1235



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/16722

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

databases: APS, WPIDS, HCAPLUS, EMBASE, MEDLINE

search terms: linolenic, eicosapentaenoic, docosahexaenoic, chondroitin, acetylglucosamine, arthritis, osteoarthritis;

also inventor name search